ArticleJournal of gastrointestinal cancer2026
Quality of Life and Experiences of Patients with Gastrointestinal Stromal Tumors (GIST) on Imatinib Treatment.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAdjuvant or palliative treatment with imatinib improved the survival of patients with rare gastrointestinal stromal tumours (GISTs) impressively. However, the impact on quality of life (QoL) and patients’ experiences with imatinib is largely unknown. We performed a survey study in order to assess QoL and experiences with imatinib treatment, comparing the adjuvant and metastatic setting.
methodsPatients with GIST who were on active imatinib completed a cross-sectional web-based survey with the following questionnaires: EORTC Quality of Life Questionnaire (QLQ-C30), Treatment Satisfaction Questionnaire for Medication (TSQM), Beliefs about Medicines Questionnaire (BMQ), Cancer Worry Scale (CWS) and Medication Adherence Report Scale (MARS).
resultsSymptom burden and the scores for the QLQ-C30 scales were similar between adjuvant (n = 19) and metastatic disease (n = 56), with a mean(SD) global QoL score of 69.2 in the entire study population (n = 77). Patients with metastatic disease experienced less side effects (63.0(20.3) versus 51.0(22.7); p = 0.035), had better global satisfaction scores (79(15.9) versus 68(18.8); p = 0.015) and are more convinced of the necessity of imatinib for controlling the disease compared to patients receiving adjuvant treatment (score 19.9(4.6) versus 17.5(3.6); p = 0.043). Approximately 3 out of 4 patients report high fear of cancer recurrence / progression, without a difference in the adjuvant or metastatic setting. Therapy adherence was high (96.1%).
conclusionPatients with GIST on imatinib treatment have good QoL but show high percentage of fear for cancer recurrence / progression. Especially patients with metastatic disease believe in the necessity of imatinib. These findings help to educate and support individual patients treated with imatinib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.